Zobrazeno 1 - 10
of 334
pro vyhledávání: ''
Autor:
Junji Tsurutani, Caleb Lee, Ian E. Krop, Shunji Takahashi, Rashmi Krishna Murthy, Alvaro Moreno-Aspitia, Javad Shahidi, Masahiro Sugihara, Haeseong Park, Yasuaki Sagara, Kenji Tamura, Lin Zhang, Charles H. Redfern, Yoshihiko Fujisaki, Hiroji Iwata, Shanu Modi, Toshihiko Doi
Publikováno v:
Journal of Clinical Oncology. 38:1887-1896
PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evalua
Autor:
Rashmi Krishna Murthy, Amelia Zelnak, Giuseppe Curigliano, Carey K. Anders, Elisavet Paplomata, Mafalda Oliveira, Eric P. Winer, Virginia F. Borges, Karen A. Gelmon, Alison Conlin, Xuebei An, Michael DiGiovanna, Sibylle Loibl, Alicia Okines, Sara A. Hurvitz, Ruth O'Regan, Philippe L. Bedard, Andrew M Wardley, Lisa A. Carey, Thomas Bachelot, Jo Al Mayor, David Cameron, A. Jo Chien, Nan Lin, Sherene Loi, Vandana G. Abramson, Suzanne McGoldrick, Erika Hamilton, Volkmar Mueller
Publikováno v:
Journal of Clinical Oncology
Scientia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 23
Lin, N U, Borges, V, Anders, C, Murthy, R K, Paplomata, E, Hamilton, E, Hurvitz, S, Loi, S, Okines, A, Abramson, V, Bedard, P L, Oliveira, M, Mueller, V, Zelnak, A, Digiovanna, M P, Bachelot, T, Chien, A J, O’regan, R, Wardley, A, Conlin, A, Cameron, D, Carey, L, Curigliano, G, Gelmon, K, Loibl, S, Mayor, J, Mcgoldrick, S, An, X & Winer, E P 2020, ' Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial ', Journal of Clinical Oncology, pp. JCO.20.00775 . https://doi.org/10.1200/JCO.20.00775, https://doi.org/10.1200/JCO.20.00775
BASE-Bielefeld Academic Search Engine
Scientia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 23
Lin, N U, Borges, V, Anders, C, Murthy, R K, Paplomata, E, Hamilton, E, Hurvitz, S, Loi, S, Okines, A, Abramson, V, Bedard, P L, Oliveira, M, Mueller, V, Zelnak, A, Digiovanna, M P, Bachelot, T, Chien, A J, O’regan, R, Wardley, A, Conlin, A, Cameron, D, Carey, L, Curigliano, G, Gelmon, K, Loibl, S, Mayor, J, Mcgoldrick, S, An, X & Winer, E P 2020, ' Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial ', Journal of Clinical Oncology, pp. JCO.20.00775 . https://doi.org/10.1200/JCO.20.00775, https://doi.org/10.1200/JCO.20.00775
BASE-Bielefeld Academic Search Engine
PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We desc
Autor:
Miguel Martin, Vicente Valero, Sara A. Hurvitz, Chiun-Sheng Huang, Daniil Stroyakovskiy, Mario Campone, Vanesa Lopez-Valverde, Peter Trask, Gonzalo Spera, Jean Francois Boileau, Chunyan Song, Peter A. Fasching, W. Fraser Symmans, Kyung Hae Jung, Joseph A. Sparano, Hans Wildiers, Thomas Boulet, Alastair M. Thompson, Karen Afenjar, Nadia Harbeck, Dennis J. Slamon
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 25
Journal of Clinical Oncology
Journal of Clinical Oncology
PURPOSE The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the treatment human epidermal growth factor receptor 2–positive stage II to III breast cance
Autor:
Hideaki Takahashi, Yuichiro Tada, Shuhei Yamada, Hiroya Ojiri, Hideaki Hirai, Takashi Matsuki, Kaori Tani, Kohei Akazawa, Robert Yoshiyuki Osamura, Shin Etsu Kamata, Daisuke Kawakita, Toshitaka Nagao, Chihiro Fushimi, Tatsuo Masubuchi, Kouki Miura, Takashi Saotome
Publikováno v:
Journal of Clinical Oncology. 37:125-134
Purpose Clinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma (SDC) is lacking because of the disease’s rarity. We assessed the efficacy and toxicity of trastuzumab plus docetaxel in patients wit
Autor:
Lisa M. Kopp, Johanna C. Bendell, Jennifer Scott, Michele M Grady, Olivia Gardner, Sumit K. Subudhi, Michael A. Carducci, David R. Wise
Publikováno v:
Journal of Clinical Oncology. 39:5039-5039
5039 Background: Standard-of-care (SOC) chemotherapy may contribute to immunosuppression by elevating intratumoral levels of adenosine, activating the A2a and A2b receptors on immune cells. Extracellular adenosine is primarily produced by the enzyme
Autor:
Michael Millward, Charlotte Lemech, Ji-Youn Han, Aflah Roohullah, Y. Kim, Paul de Souza, Jun Young Choi, Dae Ho Lee, Minseon Lee, Byoung Chul Cho, Young Kee Shin, Kyung Eui Park
Publikováno v:
Journal of Clinical Oncology. 39:TPS3157-TPS3157
TPS3157 Background: c-MET (hepatocyte growth factor (HGF) receptor) overexpression, either by gene amplification, or mutation is associated with oncogenic transformation in numerous malignancies including lung, gastric, skin, renal, colorectal, and p
Autor:
Johann S. de Bono, Maura Rossetti, Jean-Pascal Machiels, Noémie Wald, Esha A. Gangolli, Joanne Lager, Erol Wiegert, Thubeena Manickavasagar, Nicola McIntyre, Chiara Martinoli, Ariane Migeotte, Laurence Buisseret, Sylvie Rottey, Brant Delafontaine
Publikováno v:
Journal of Clinical Oncology. 39:2562-2562
2562 Background: Tumors produce high levels of extracellular adenosine which suppress anti-tumor immune responses. Blocking A2A receptors, predominantly expressed on tumor-infiltrating immune cells, can reverse the immunosuppressive effect of adenosi
Autor:
Matthew Ingham, Lauren Franks, Brian A. Van Tine, Jay Oza, Shahnaz Singh-Kandah, Susana Hernandez, Swathi Balaji, Sahil D Doshi, Shing Mirn Lee, Edwin Choy, Peter John Oppelt, Gary K. Schwartz, Zoe Singer
Publikováno v:
Journal of Clinical Oncology. 39:11513-11513
11513 Background: Well-differentiated/dedifferentiated liposarcoma (WD/DD LPS), a sarcoma of adipocytic origin, lacks effective treatment options for advanced disease. Pazopanib, a receptor tyrosine kinase (RTK) inhibitor active upon angiogenic RTKs,
Autor:
Erin S. Murphy, V. Tatineni, Yasmeen Rauf, David M. Peereboom, Xuefei Jia, John H. Suh, Patrick Joseph O'Shea, Samuel T. Chao, Manmeet Ahluwalia
Publikováno v:
Journal of Clinical Oncology. 39:2030-2030
2030 Background: Renal cancer is the fourth most common cause of metastatic tumors to the brain. Tyrosine kinase inhibitors (TKIs) targeting VEGFR and other receptors, such as sunitinib, pazopanib, etc., have been used as first line for renal cell ca
Autor:
Fredrik Schjesvold, Michele Cavo, Xavier Leleu, Jesús F. San-Miguel, Jeffrey Sy. Huang, Paul G. Richardson, Meral Beksac, Jiri Minarik, Aurore Perrot, Ivan Spicka, Kenneth C. Anderson, Helgi van de Velde, H. Miles Prince, Philippe Moreau, Franck Dubin, Cheng Zheng, Meletios A. Dimopoulos
Publikováno v:
Journal of Clinical Oncology. 39:8017-8017
8017 Background: Isa is an approved monoclonal antibody that binds to a specific epitope on the CD38 receptor. The Phase 3 ICARIA-MM study (NCT02990338) demonstrated significantly improved progression-free survival (PFS) with Isa-Pd vs Pd ( P= 0.001)